Extended Data Fig. 6. viFSP1 shows the synergistic effect toward ferroptosis in numerous cancer cells.
a. DepMap database analysis. AIFM2 (FSP1) expression and sensitivity of GPX4 inhibitors (RSL3 and ML210) are shown and cell lines used in this study are highlighted. b. TISMO data analysis. The baseline expression of Gpx4 and Fsp1 are shown and cell lines used in this study are highlighted. c. Immunoblot analysis of GPX4, FSP1, and VCP expression in various cell lines (from a single experiment). d. Cell viability of various cell lines treated with RSL3 and/or viFSP1 for 24 h. Lip-1 was used as a ferroptosis inhibitor. e. Immunoblot analysis of GPX4, FSP1, actin and VCP expression in B16F10 and 4T1 cells from a single experiment. DKO: Gpx4-KO/Fsp1-KO. f. Cell viability of 4T1 Gpx4-KO cells stably expressing hFSP1 or mFSP1, and B16F10 DKO cells stably expressing hFSP1 or mFSP1 treated with viFSP1 for 48 h. Lip-1 was used as ferroptosis inhibitor. g. Cell viability of B16F10 DKO cells stably expressing mGPX4 or mGPX4 U46C treated with RSL3 for 24 h. h. Representative immunoblot analysis of GPX4, and VCP expression in SW620 cells from a single experiment (left). Cell viability of SW620 wildtype cells or GPX4-KO treated with viFSP1 for 48 h (right). i. Cell viability of murine cell lines treated with JKE-1674 and/or viFSP1 (5 µM) and Lip-1 (0.5 µM) for 24 h. j. Cell viability of human cancer cell lines treated with JKE-1674 and/or viFSP1 (5 µM) and Lip-1 (0.5 µM) for 24 h. Data represents the mean ± SD of 3 wells of a 96-well plate from one out of 2 independent experiments (d,f,g,h,i,j).